Big pharmacy brands are quietly selling off more branches than ever before — and it could reshape how local communities access medicines. But here’s where it gets controversial: while big chains are offloading stores, smaller independents and first-time buyers are stepping in, raising big questions about who will really control community pharmacy in the next few years.
In 2025 so far, large corporate and multiple operators have driven the majority of pharmacy sale activity, accounting for around 71% of all sales instructions, while independent owners have initiated only about 19%. This marks a major change from 2024, when independents held a similar majority share of sale instructions, and suggests a clear swing from smaller owner-led disposals to big chains putting more branches on the market. The remainder of sales instructions in 2025 has largely come from groups looking to dispose of outlier or non-core branches, indicating a strategy of tightening portfolios rather than expanding them.
According to the report, buyer demand is being led by first-time purchasers, who represent about 76% of new registrations to buy a pharmacy. Independent owners follow at around 12%, with investors making up roughly 8%, and the final 4% consisting of group owners, former owners, and larger multiples returning to the market. And this is the part most people miss: while big chains are selling, it is often entrepreneurial individuals and smaller operators who are lining up to acquire these businesses, potentially changing the balance of power in community pharmacy over time.
When looking at deals that actually complete, expanding independent owners are at the front of the pack, accounting for about 44% of completed purchases. First-time buyers complete around 29% of deals, with group owners responsible for about 27%, showing that growth is being driven most strongly by independents who already own pharmacies and are looking to scale. This pattern suggests that experienced operators still have an edge when it comes to navigating finance, due diligence, and the practicalities of taking a deal from offer to completion, even though first-time buyers make up the bulk of initial enquiries.
The report notes a modest downward trend in average pharmacy goodwill values achieved so far in 2025 compared with previous years. One key reason is the increase in disposal instructions from corporate and multiple operators, which has expanded the number of pharmacies available and reduced the intensity of competition between buyers. At the same time, ongoing concerns about profitability, rising costs, and overall financial performance are making buyers more cautious, echoing the hesitancy seen in the 2024 sales market and reinforcing a more risk-aware attitude to acquisition.
Real-world examples show how this plays out on the ground. One pharmacy multiple, Jhoots, has sold a number of branches this year, with Allied Pharmacies announcing the acquisition of 60 of its stores in early November 2025. Deals of this scale highlight how quickly ownership can shift from one large operator to another group, and raise the question of whether communities will see genuine diversity in pharmacy ownership or simply a reshuffle among bigger players.
For the National Pharmacy Association, these trends are a worrying signal. Its director of corporate affairs has argued that the high number of owners valuing or selling their businesses is strong evidence of intense financial pressure and ongoing uncertainty around medicines supply. At the same time, there is concern that headline transaction activity does not reveal much about the actual prices being achieved or the longer-term financial stability of those pharmacies once they change hands, leaving a big question mark over the sector’s resilience.
There is some cautious hope that growth in pharmacy services could improve the outlook, but this optimism depends heavily on future government policy and investment. If funding and support for clinical and patient-facing services increase, pharmacies could diversify revenue and improve sustainability; if not, the current wave of sales might be just the beginning of further consolidation. This is where opinions may sharply diverge: some see the changing market as an opportunity for innovation, while others view it as a warning sign of systemic underfunding.
The Independent Pharmacies Association has also weighed in, questioning how representative the broker’s data really is, assuming the figures relate only to that firm’s own client base and therefore reflect a relatively small sample. From what the IPA reports seeing among its own members, independent groups can expand rapidly, completing multiple acquisitions in a relatively short period of time, which may paint a more optimistic picture for agile, well-run independents. That contrast raises a controversial point: is the current market primarily a story of decline, or of nimble operators seizing a rare window of opportunity?
So what do you think: is the surge in big chains selling branches a red flag that the community pharmacy model is under unsustainable pressure, or a healthy reshaping that will ultimately empower independents and new entrants? Do you feel more comfortable with pharmacies owned by large corporates, or do you trust independents to deliver better local care and stability? Share whether you agree or disagree with the idea that this trend could actually strengthen the sector in the long run — and why.
